Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of deep vein thrombosis. [PDF]
Cochrane Database Syst Rev, 2023 BACKGROUND Deep vein thrombosis (DVT) is a condition in which a clot forms in the deep veins, most commonly of the leg. It occurs in approximately one in 1000 people.
Xiaoqin Wang +11 more
semanticscholar +2 more sources
Three cases of neutralization of factor Xa inhibitors with andexanet alfa under rotational thromboelastography monitoring [PDF]
Acute Medicine & SurgeryBackground Factor Xa inhibitors are direct oral anticoagulants that are extremely useful in clinical applications, safe, and do not require dose adjustment.
Takeshi Yagi +9 more
doaj +2 more sources
Efficacy of Factor Xa Inhibitors Versus Placebo in Thromboprophylaxis for Cancer-Associated Thromboembolism: A Systematic Review and Meta-analysis [PDF]
Clinical and Applied Thrombosis/HemostasisBackground Cancer patients are at significantly increased risk of venous thromboembolism (VTE), a leading cause of morbidity and mortality in this population.
Amna Kamil MBBS +8 more
doaj +2 more sources
Predictors of hematoma expansion in intracerebral hemorrhage associated with factor Xa inhibitors [PDF]
Frontiers in NeurologyBackgroundImproving the outcomes of patients with intracerebral hemorrhage (ICH) associated with factor Xa inhibitors remains a clinical challenge. Andexanet alfa, a specific reversal agent for factor Xa inhibitors, has the potential to mitigate hematoma
Yoji Komatsu +9 more
doaj +2 more sources
Monitoring anti-factor Xa activity in patients with chronic thromboembolic pulmonary hypertension treated with factor Xa inhibitors [PDF]
Scientific ReportsDirect oral anticoagulants (DOACs) have been used clinically in patients with chronic thromboembolic pulmonary hypertension (CTEPH) for secondary prevention after acute venous thromboembolism, although the data are limited.
Yoshihisa Nakano +8 more
doaj +2 more sources
The new factor Xa inhibitor: Apixaban
Journal of Pharmacology and Pharmacotherapeutics, 2014 Cardiovascular diseases are still the most important cause of morbidity and mortality worldwide and anti-thrombotic treatment is widely used as a result. The currently used drugs include heparin and its derivatives, vitamin K antagonists, though efficacious, have their own set of limitations like unpredictable pharmacokinetic profile, parenteral route (
Sangeeta Bhanwra, Kaza Ahluwalia
openalex +5 more sources
Application of Molecular Modeling to Development of New Factor Xa Inhibitors [PDF]
BioMed Research International, 2015 In consequence of the key role of factor Xa in the clotting cascade and absence of its activity in the processes that do not affect coagulation, this protein is an attractive target for development of new blood coagulation inhibitors.
Alexey V. Sulimov +10 more
core +4 more sources
Japanese Journal of Thrombosis and Hemostasis, 2003 Takashi Koizumi, Masahiko Uchida
openalex +3 more sources
Andexanet alfa for the reversal of factor Xa inhibitors
Expert Opinion on Biological Therapy, 2019 Introduction: Andexanet alfa is a recombinant modified factor Xa protein that has been developed to reverse factor Xa inhibitors. Since May 2018, the FDA has approved its utilization in patients treated with apixaban and rivaroxaban in case of life ...
Julien Favresse +9 more
openalex +3 more sources
Factor Xa Inhibitors Versus Vitamin K Antagonists in Atrial Fibrillation Patients with End-Stage Kidney Disease on Dialysis: A Meta-Analysis [PDF]
Clinical and Applied Thrombosis/HemostasisBackground Atrial fibrillation (AF) is prevalent among patients with end-stage kidney disease (ESKD) undergoing dialysis, and both conditions are associated with a heightened risk of cardiovascular diseases.
Meimei Xiong MS +2 more
doaj +2 more sources